beta
Trial Radar AI
Clinical Trial NCT06831929 (HPV) for HPV Vaccine is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

HPV Ends Here: Increasing Uptake of the HPV Vaccine 2,232 Vaccine Study Randomized

Recruiting
Clinical Trial NCT06831929 (HPV) is an interventional study for HPV Vaccine that is recruiting. It started on February 28, 2025 with plans to enroll 2,232 participants. Led by University of California, Davis, it is expected to complete by December 31, 2026. The latest data from ClinicalTrials.gov was last updated on April 25, 2025.
Brief Summary
Develop, implement, and evaluate a culturally tailored multilevel intervention to increase uptake of the HPV vaccine among eligible patients ages 10-12 of the University of California, Davis Health Community Physician (UCDH CP) primary care practices using a randomized controlled trial design.
Detailed Description
The goal of this study is to use an evidence-based approach to develop, implement and evaluate a ML intervention on increasing HPV vaccine uptake among UCDH CP patients ages 10-12.

Aim 1. Refine and finalize a parent, primary care team and clinic ML intervention to increase uptake and completion of the HPV vaccine series among adolescent patients of the UCDH CP practices. In Phase 1, semi-structured qualitative inte...

Show More
Official Title

Human Papillomavirus Ends Here: A Multilevel Intervention to Increase Uptake of the HPV Vaccine Among Adolescents

Conditions
HPV Vaccine
Other Study IDs
NCT ID Number
NCT06831929
Start Date (Actual)
2025-02-28
Last Update Posted
2025-04-25
Completion Date (Estimated)
2026-12-31
Enrollment (Estimated)
2,232
Study Type
Interventional
PHASE
N/A
Status
Recruiting
Keywords
HPV
Human Papillomavirus
Primary Purpose
Prevention
Design Allocation
Randomized
Interventional Model
Parallel
Masking
Single
Arms / Interventions
Participant Group/ArmIntervention/Treatment
No InterventionControl Arm
These clinics will not receive any intervention and will continue with care as usual.
N/A
ExperimentalIntervention Arm
These clinics will receive the multilevel intervention which will include tailored parent/patient education, appointment scheduling assistance, and primary care team trainings.
Intervention Arm
Within the intervention clinics, parents of patients between the ages of 10-12 (who are eligible for the HPV vaccine) will receive a culturally tailored customized HPV vaccine message and testimonial video from a patient/survivor of an HPV associated cancer (e.g., oropharyngeal, or cervical) via the MyChart patient portal. Parents will also receive a personal call from the research coordinator to remind them that the...Show More
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Primary Outcome: Evaluation
Number of participants who initiate and complete the HPV vaccine series
One year
Participation Assistant
Eligibility Criteria

Eligible Ages
Child
Minimum Age
10 Years
Eligible Sexes
All
Accepts Healthy Volunteers
Yes

• Clinic patients between the ages of 10-12 who are eligible for the HPV vaccine

• Clinic patients who already received the HPV vaccine or with any contraindication to the HPV vaccine.
University of California, Davis logoUniversity of California, Davis235 active studies to explore
National Cancer Institute (NCI) logoNational Cancer Institute (NCI)3019 active studies to explore
Study Central Contact
Contact: Ramneek Kahlon, BS, 9167312578, [email protected]
1 Study Locations in 1 Countries

California

University of California Davis Health, Sacramento, California, 95817, United States
Julie HT Dang, PhD, Contact, [email protected]
Recruiting